Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 112Lymphoma, Large B-Cell, Diffuse 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Leukemia 47Burkitt Lymphoma 45Lymphoma, Non-Hodgkin 35Lymphoma, Mantle-Cell 28Lymphoma, Follicular 27Hodgkin Disease 22Neuroblastoma 19Central Nervous System Neoplasms 19Sarcoma 18Lymphoma, B-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Neoplasms 10Multiple Myeloma 10Dendritic Cell Sarcoma, Interdigitating 10Sarcoma, Ewing 9Rhabdomyosarcoma 9Retinoblastoma 9Medulloblastoma 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Biphenotypic, Acute 8Recurrence 7Neuroectodermal Tumors, Primitive, Peripheral 7Lymphoma, T-Cell 7HIV Infections 7

Interventions

trametinib 1dabrafenib 1Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ganglioneuroma × Vincristine × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡